Ravicti
glycerol phenylbutyrate
Table of contents
Overview
Ravicti is a medicine used to manage urea cycle disorders in adults and children, when the diseases cannot be managed by changes in diet alone. Patients with urea cycle disorders are not able to get rid of waste nitrogen from the body because they lack some liver enzymes. In the body, waste nitrogen is turned into ammonia, which is harmful when it accumulates. Ravicti is used in patients who lack one or more of the following enzymes: carbamoyl phosphate synthase-I, ornithine carbamoyltransferase, argininosuccinate synthetase, argininosuccinate lyase, arginase I and ornithine translocase.
Ravicti contains the active substance glycerol phenylbutyrate.
Urea cycle disorders are rare, and Ravicti was designated an ‘orphan medicine’ (a medicine used in rare diseases) for several forms of the disease on 10 June 2010. Further information on the orphan designations can be found on the European Medicines Agency’s website.
-
List item
Ravicti : EPAR - Summary for the public (PDF/78.75 KB)
First published: 18/12/2015
Last updated: 29/01/2019 -
-
List item
Ravicti : EPAR - Risk-management-plan summary (PDF/211.64 KB)
First published: 18/12/2015
Last updated: 21/01/2022
Authorisation details
Product details | |
---|---|
Name |
Ravicti
|
Agency product number |
EMEA/H/C/003822
|
Active substance |
glycerol phenylbutyrate
|
International non-proprietary name (INN) or common name |
glycerol phenylbutyrate
|
Therapeutic area (MeSH) |
Urea Cycle Disorders, Inborn
|
Anatomical therapeutic chemical (ATC) code |
A16AX09
|
Orphan |
This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation. |
Publication details | |
---|---|
Marketing-authorisation holder |
Immedica Pharma AB
|
Revision |
15
|
Date of issue of marketing authorisation valid throughout the European Union |
26/11/2015
|
Contact address |
Solnavagen 3H |
Product information
19/10/2022 Ravicti - EMEA/H/C/003822 - IAIN/0043
This medicine’s product information is available in all official EU languages.
Select ‘available languages’ to access the language you need.
Product information documents contain:
- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).
You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.
Pharmacotherapeutic group
Other alimentary tract and metabolism products
Therapeutic indication
Ravicti is indicated for use as adjunctive therapy for chronic management of patients with urea cycle disorders (UCDs) including deficiencies of carbamoyl phosphate-synthase-I (CPS), ornithine carbamoyltransferase (OTC), argininosuccinate synthetase (ASS), argininosuccinate lyase (ASL), arginase I (ARG) and ornithine translocase deficiency hyperornithinaemia-hyperammonaemia homocitrullinuria syndrome (HHH) who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.
Ravicti must be used with dietary protein restriction and, in some cases, dietary supplements (e.g., essential amino acids, arginine, citrulline, protein-free calorie supplements).